25 completed, 12 terminated, 3 unknown, 3 withdrawn. 14 Phase 3, 12 Phase 2, 9 Phase 4, 7 Phase 1, 3 Early Phase 1.
Follow brodalumab: new trials by email Literature Review of brodalumab trials Research Report on brodalumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Brodalumab in the Treatment of Immune-Related Adverse Events Brodalumab, CT scan - Breast Cancer, Esophageal Cancer | Phase 1 | Recruiting | Brian Henick, MD | 11 | 2025-03-11 | 2026-05-13 |
| Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis Brodalumab, Ustekinumab, Placebo - Psoriasis | Phase 3 | Terminated | LEO Pharma | 12 | 2022-12-07 | 2025-03-14 |
| Adjusted Brodalumab Dose Compared With Standard Brodalumab Dose in Subjects With Moderate-to-severe Plaque Psoriasis and ≥120 kg Body Weight Brodalumab - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 385 | 2022-07-21 | 2026-04-24 |
| Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity Brodalumab, Matched cohort - Psoriasis | Active not recruiting | Bausch Health Americas, Inc. | 394 | 2021-10-22 | 2026-09-30 | |
| Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa Brodalumab - Hidradenitis Suppurativa, Acne Inversa | Early Phase 1 | Completed | Rockefeller University | 4 | 2021-08-05 | 2022-07-27 |
| Efficacy and Safety of Brodalumab Compared With Guselkumab in the Treatment of Plaque Psoriasis After Inadequate Response to Ustekinumab Brodalumab, Placebo, Guselkumab - Plaque Psoriasis, Psoriasis Vulgaris | Phase 4 | Terminated | LEO Pharma | 113 | 2020-12-17 | 2025-03-14 |
| Brodalumab in Palmoplantar Psoriasis Brodalumab - Palmoplantar Psoriasis | Phase 4 | Unknown | First OC Dermatology | 10 | 2020-12-01 | 2020-11-16 |
| Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis Secukinumab, Ixekizumab, Brodalumab - Psoriasis, Psoriasis Vulgaris | Phase 4 | Completed | Radboud University Medical Center | 244 | 2020-08-20 | 2026-03-17 |
| An Alternative Dose Interval Study in Participants With Hidradenitis Suppurativa Receiving Brodalumab Brodalumab - Hidradenitis Suppurativa | Early Phase 1 | Withdrawn | Rockefeller University | 2020-02-03 | 2020-09-04 | |
| An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects Brodalumab - Psoriasis | Phase 4 | Active not recruiting | Bausch Health Americas, Inc. | 2 | 2020-01-24 | 2025-09-16 |
| A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen Brodalumab - Psoriasis | Completed | Bausch Health Americas, Inc. | 252 | 2019-09-30 | 2022-07-15 | |
| A Study of KHK4827 in Subjects With Palmoplantar Pustulosis KHK4827, Placebo - Palmoplantar Pustulosis | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 126 | 2019-08-10 | 2023-02-14 |
| Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab Brodalumab - Hidradenitis Suppurativa | Early Phase 1 | Completed | Rockefeller University | 10 | 2019-05-28 | 2020-06-04 |
| A Phase 3 Study of KHK4827 in Patients With Systemic Sclerosis KHK4827, Placebo - Moderate to Severe Systemic Sclerosis | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 100 | 2019-05-23 | 2025-07-11 |
| Treatment of Moderate Hidradenitis Suppurativa Brodalumab - Hidradenitis Suppurativa | Phase 2 | Unknown | Florida Academic Dermatology Centers | 20 | 2019-05-01 | 2019-04-10 |
| Effect of Brodalumab Compared to Placebo on Vascular Inflammation in Moderate-to-severe Psoriasis Brodalumab, Placebos - Psoriasis | Phase 4 | Unknown | Aarhus University Hospital | 50 | 2018-09-15 | 2019-07-10 |
| A Trial Comparing the Efficacy of Subcutaneous Injections of Brodalumab to Oral Administrations of Fumaric Acid Esters in Adults With Moderate to Severe Plaque Psoriasis Brodalumab, Fumaric acid esters - Psoriasis Vulgaris | Phase 4 | Completed | LEO Pharma | 210 | 2017-11-03 | 2025-03-13 |
| Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies Brodalumab - Psoriasis | Phase 4 | Completed | Icahn School of Medicine at Mount Sinai | 39 | 2017-10-31 | 2021-03-10 |
| A Study of KHK4827 in Patients With Systemic Sclerosis KHK4827 - Systemic Sclerosis | Phase 1 | Completed | Kyowa Kirin Co., Ltd. | 8 | 2017-10-06 | 2025-07-11 |
| LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe Psoriasis Brodalumab, Comparator Drug (non-biologic IL-17 inhibitors) - Psoriasis | Enrolling by invitation | Bausch Health Americas, Inc. | 3500 | 2017-07-25 | 2025-09-16 |
Showing 20 of 47. Sign in to see all of them.
Psoriasis (23) · Arthritis, Psoriatic (4) · Hidradenitis Suppurativa (4) · Arthritis, Rheumatoid (3) · Asthma (3) · Axial Spondyloarthritis (2) · Crohn Disease (2) · Scleroderma, Systemic (2) · Arthritis (1) · Autoimmune Diseases (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Colonic Neoplasms (1) · Connective Tissue Diseases (1) · Esophageal Neoplasms (1)
Bausch Health Americas, Inc. (13) · Kyowa Kirin Co., Ltd. (10) · Amgen (9) · LEO Pharma (4) · Rockefeller University (3) · Aarhus University Hospital (1) · Brian Henick, MD (1) · First OC Dermatology (1) · Florida Academic Dermatology Centers (1) · Icahn School of Medicine at Mount Sinai (1) · Kyowa Kirin Korea Co., Ltd. (1) · MedDerm Associates (1) · Radboud University Medical Center (1)
United States (23) · Canada (14) · France (12) · Poland (12) · Japan (10) · Belgium (9) · Australia (7) · Germany (7) · Greece (7) · Hungary (7) · Netherlands (7) · Spain (7) · Italy (6) · Russia (5) · Czechia (4)
John W Frew, MD (2) · Varsha Bhatt (2) · Anya Loncaric (1) · Brian Henick, MD (1) · Elke de Jong, MD, PhD (1) · Mark Lebwohl, MD (1) · Martin Barbeau (1) · Michelle T Pelle, M.D. (1) · Yael Renert-Yuval, MD (1)
PMID 32207067, PMID 26422722, PMID 30328108, PMID 30471012, PMID 34606048, PMID 39264399, PMID 24286136, PMID 25313095, PMID 26547109, PMID 31493163, PMID 33548397, PMID 33827787, PMID 34656148, PMID 36130275, PMID 36997069, PMID 38300408, PMID 38954226, PMID 42543660, PMID 42577288
2019 (3), 2014 (1), 2016 (1), 2017 (1), 2023 (1)